(580 days)
Not Found
No
The description mentions "Color-coded mapping of acetowhitening intensity and duration" and "Pseudo-Color Imaging (PCI) feature," which are image processing techniques, but there is no mention of AI, ML, or any learning algorithms. The performance studies focus on technical specifications and comparison to conventional colposcopy, not on the performance of an AI/ML model.
No.
The device is described as an imaging tool for diagnosis and documentation, not for treatment.
Yes
The device is a digital colposcope used to image the cervix and lower genital tract to detect abnormal appearances consistent with neoplasia, often with directed biopsy, which is a diagnostic purpose.
No
The device description explicitly mentions hardware components like an LED illuminator, a CCD camera, imaging optics, a color monitor, and a color touch screen, indicating it is a physical device with integrated software, not software-only.
Based on the provided information, the DySIS with Pseudo-Color Imaging (PCI) device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- DySIS Function: The DySIS device is a digital colposcope that directly images the cervix and lower genital tract in vivo (within the living body). It uses light and magnification to visualize the tissue.
- No Sample Analysis: The device does not analyze samples taken from the patient. It is a direct imaging tool used during a physical examination.
Therefore, while it is a medical device used in the diagnostic process, it does not fit the definition of an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
DySIS with Pseudo-Color Imaging (PCI) is a digital colposcope designed to image the cervix and lower genital tract under illumination and magnification. Colposcopy is indicated for women with an abnormal Pap smear in order to affirm normality or detect abnormal appearances consistent with neoplasia, often with directed biopsy.
The PCI feature is an adjunctive tool for displaying areas of acetowhitening. It is a tool that should NOT be used as a substitute for a thorough colposcopic evaluation.
Product codes (comma separated list FDA assigned to the subject device)
85HEX
Device Description
DySIS offers non-patient contact, fully digital and high-resolution imaging of the cervix. The field of view is illuminated by an LED; a CCD camera coupled with the imaging optics provides crisp magnified color images. The images can be viewed on a color monitor and on the color touch screen that provides the means to control the device operation.
DySIS offers digital tools to fully document the colposcopic examination:
- Capturing of images for review, storage and printing, video recording.
- Advanced magnification and imaging.
- Operator's annotation of suspicious sites.
- Color-coded mapping of acetowhitening intensity and duration.
- Database that allows storing and retrieving identification and examination data.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Optical imaging / Digital imaging
Anatomical Site
vagina, cervix, and external genitalia / cervix and lower genital tract
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Test results using patient data indicate that the device meets performance specifications related to image registration, acetic acid timing errors, and range of PCI values.
Importantly, the study using retrospective patient data did not demonstrate that the PCI feature is superior to conventional colposcopy in helping the clinician target sites with suspected CIN for biopsy. Therefore, use of the PCI feature is not a substitute for conventional colposcopy. Consequently, the device is designed so that the clinician must perform a standard colposcopy and identify sites for biopsy before he/she can view the PCI image.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical Tests Supporting Substantial Equivalence:
a) LED temperature: Thermal output was measured on a piece of white paper placed at working distance. The temperature at the middle of the paper was measured with two instruments. The paper did not experience any significant increase in temperature after one hour of continuous exposure.
b) Timing Tolerance: This experiment tested the effect of two delay scenarios. The first, imaging delay, occurs when there is a delay between the time of acetic acid delivery and the start of imaging. The second, acetic acid delay, occurs when imaging is started before acetic acid delivery. In both cases, differences from AUC values where no delay occurred were small and not statistically significant.
c) Acetic acid concentration: This experiment tested the difference in acetowhitening between 3% and 5% acetic acid solutions. As expected the 5% solution exhibited a more extreme aceto-whitening effect. Overall, the experiment indicated that the DySIS map is capable of accurately depicting the aceto-whitening effect regardless of whether a 3% or 5% acetic acid solution is used.
d) Color Calibration: This tested the effects of moving the calibration test card closer or further than the standard focusing distance of 30 cm. An operator was asked to focus from a random distance between +3 mm from focusing distance. The results indicated that Pixel Value (a function of reflected LED brightness) fell within the desired tolerance band of ±2 from points within this range.
e) Image Alignment: In order to test the effectiveness of the alignment algorithm, which is used to account for small movements during the exam, one cervical image was sequentially distorted ten times. The distortions totaled a 20% change from the original, which is equivalent to 7 mm of actual movement. The algorithm was able to compensate to 0.4 mm, well within the acceptable level.
Clinical Tests Supporting Substantial Equivalence:
No clinical studies were conducted to demonstrate improved clinical performance using the PCI feature.
Test results using patient data indicate that the device meets performance specifications related to image registration, acetic acid timing errors, and range of PCI values.
Importantly, the study using retrospective patient data did not demonstrate that the PCI feature is superior to conventional colposcopy in helping the clinician target sites with suspected CIN for biopsy. Therefore, use of the PCI feature is not a substitute for conventional colposcopy. Consequently, the device is designed so that the clinician must perform a standard colposcopy and identify sites for biopsy before he/she can view the PCI image.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 884.1630 Colposcope.
(a)
Identification. A colposcope is a device designed to permit direct viewing of the tissues of the vagina and cervix by a telescopic system located outside the vagina. It is used to diagnose abnormalities and select areas for biopsy. This generic type of device may include a light source, cables, and component parts.(b)
Classification. Class II (special controls). The device, when it is a standard colposcope (or colpomicroscope) that uses only a white light source, does not use filters other than a green filter, does not include image analysis software, and is not smartphone-based, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.
0
510(k) summary
MAR 1 0 2011
Ko92433 pa
1. Submitter Identification
| Submitter | Forth Photonics, Ltd
Alba Innovation Centre
Livingston, Scotland UK |
|----------------|---------------------------------------------------------------------------|
| Contact Person | Joshua Freeman |
| Phone | +1 781 329 2993 |
| Fax | +1 781 329 2968 |
| Date Prepared | 02/04/2011 |
2. Device Identification
| Name of Device | DySIS |
|---|---|
| Trade/Proprietary Name | DySIS |
| Common or Usual Name | Digital Colposcope |
| Classification | Colposcope (21CFR884.1630) |
| Product Code | 85HEX |
3. Predicate Devices
| Manufacturer | Model | Trade Name | 510(k) |
|---|---|---|---|
| Welch-Allyn | 88000/8900 | Video Colposcope | K955635 |
| Cooper Surgical | CooperSurgical Digital Colposcopy System | K972630 | |
| Goldway | SLC-2000 | Goldway Digital Video Colposcope Imaging | |
| System | K021153 |
The indications for use for Forth Photonics DySIS digital colposcope are substantially equivalent to the indications for use of the predicate devices.
4. Executive Summary
DySIS is a digital colposcope intended to provide magnified viewing of the vagina, cervix and external genitalia. DySIS is used to diagnose abnormalities and select areas for biopsy. DySIS acquires, displays and documents high-resolution still and sequentially
1
K09 2433 page 2 of 5
captured images and videos and provides color-coded mapping of the acetowhitening effect to facilitate assessment and documentation.
5. Device Description
DySIS offers non-patient contact, fully digital and high-resolution imaging of the cervix. The field of view is illuminated by an LED; a CCD camera coupled with the imaging optics provides crisp magnified color images. The images can be viewed on a color monitor and on the color touch screen that provides the means to control the device operation.
DySIS offers digital tools to fully document the colposcopic examination:
- Capturing of images for review, storage and printing, video recording .
- Advanced magnification and imaging .
- Operator's annotation of suspicious sites .
- Color-coded mapping of acetowhitening intensity and duration .
- Database that allows storing and retrieving identification and examination data .
6. Indications for Use statement
DySIS with Pseudo-Color Imaging (PCI) is a digital colposcope designed to image the cervix and lower genital tract under illumination and magnification. Colposcopy is indicated for women with an abnormal Pap smear in order to affirm normality or detect abnormal appearances consistent with neoplasia, often with directed biopsy. The PCI feature is an adjunctive tool for displaying areas of acetowhitening. It is a tool that should NOT be used as a substitute for a thorough colposcopic evaluation.
7. Comparison to predicate devices
The CooperSurgical, Welch-Allyn and Goldway colposcopes permit magnified viewing of the tissues of the vagina, the cervix and external genitalia to identify atypical sites and select sites to biopsy. The Welch-Allyn and Goldway colposcopes feature viewing exclusively via a monitor, whereas the CooperSurgical colposcope also allows direct viewing. These systems also provide documentation capabilities, such as still image and/or video capture (all three) and reporting of the colposcopic predictions
2
K092433 page 3 of 5
(CooperSurgical and Goldway) and annotation/measurement tools (CooperSurgical). Further, DySIS offers optional color-coded mapping of acetowhitening by processing digital images, in a way similar to that of other medical devices. The DySIS color-coded mapping feature does not interfere with the view of the cervix during the colposcopic exam. It provides the colposcopist with an alternative representation and enhancement of the images captured during the acetowhitening effect. Specifically, the pseudocolor map depicts the extent, intensity and duration of the acetowhitening effect; however, it is not intended to automate the acetowhitening evaluation.
Use of the PCI feature is NOT a substitute for the conventional colposcopic view. When using the DySIS with Pseudo-Color Imaging (PCI) the clinician must ALWAYS first conduct a thorough colposcopic exam and identify and select areas for biopsy. The clinician may then use the Pseudo-Color Imaging (PCI) feature to (possibly) identify one or more additional biopsy sites, but may NEVER cancel any of the biopsy sites initially identified with the conventional colposcopic view.
DySIS is a fully digital colposcope, integrating a high-resolution CCD sensor, LED illumination and additional options to improve ergonomics and documentation of the colposcopic examination.
The provided technical improvements do not raise any questions of safety or effectiveness.
8. Non-Clinical Tests Supporting Substantial Equivalence
DySIS has undergone extensive testing to show substantial equivalence to existing colposcopes. The following tests have been performed:
a) LED temperature: Thermal output was measured on a piece of white paper placed at working distance. The temperature at the middle of the paper was measured with two instruments. The paper did not experience any significant increase in temperature after one hour of continuous exposure.
b) Timing Tolerance: This experiment tested the effect of two delay scenarios. The first, imaging delay, occurs when there is a delay between the time of acetic acid delivery and the start of imaging. The second, acetic acid delay, occurs when imaging is
3
started before acetic acid delivery. In both cases, differences from AUC values where no delay occurred were small and not statistically significant.
c) Acetic acid concentration: This experiment tested the difference in acetowhitening between 3% and 5% acetic acid solutions. As expected the 5% solution exhibited a more extreme aceto-whitening effect. Overall, the experiment indicated that the DySIS map is capable of accurately depicting the aceto-whitening effect regardless of whether a 3% or 5% acetic acid solution is used.
d) Color Calibration: This tested the effects of moving the calibration test card closer or further than the standard focusing distance of 30 cm. An operator was asked to focus from a random distance between +3 mm from focusing distance. The results indicated that Pixel Value (a function of reflected LED brightness) fell within the desired tolerance band of ±2 from points within this range.
Image Alignment: In order to test the effectiveness of the alignment e) algorithm, which is used to account for small movements during the exam, one cervical image was sequentially distorted ten times. The distortions totaled a 20% change from the original, which is equivalent to 7 mm of actual movement. The algorithm was able to compensate to 0.4 mm, well within the acceptable level.
9, Clinical Tests Supporting Substantial Equivalence
No clinical studies were conducted to demonstrate improved clinical performance using the PCI feature.
Test results using patient data indicate that the device meets performance specifications related to image registration, acetic acid timing errors, and range of PCI values.
Importantly, the study using retrospective patient data did not demonstrate that the PCI feature is superior to conventional colposcopy in helping the clinician target sites with suspected CIN for biopsy. Therefore, use of the PCI feature is not a substitute for conventional colposcopy. Consequently, the device is designed so that the clinician must perform a standard colposcopy and identify sites for biopsy before he/she can view the PCI image.
4
K092433 page 5 of 5
The device labeling clearly states that before viewing the PCI image, the clinician should ALWAYS perform colposcopy and commit to biopsy sites on the basis of the colposcopic evaluation. Labeling also states that colposcopically-directed biopsy sites should NEVER be cancelled on the basis of the PCI image
10. Conclusion
The Forth Photonics DySIS digital colposcope has equivalent indications for use and principles of operation to the referenced predicate devices. The additional features of the DySIS digital colposcope over the predicate devices do not raise any questions of safety and effectiveness. Thus, the DySIS digital colposcope is substantially equivalent to legally marketed colposcopes.
5
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of an eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002
Forth Photonics Hellas SA % Ms. Amy Aulwes Vice President Health Policy Associates, Inc. 690 Canton Street. Suite 302 WESTWOOD MA 02090
Re: K092433
Trade Name: DySIS Digital Colposcope Regulation Number: 21 CFR §884.1630 Regulations Name: Colposcope . Regulatory Class: II Product Code: HEX Dated: January 4, 2010 Received: January 5, 2010
MAR 1 0 2719
Dear Ms. Aulwes:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The J general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related
6
Page 2
adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Hubert Lemmer MD
Herbert P. Lerner, M.D., Director (Acting) Division of Reproductive, Gastro-Renal and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
Indications for Use
510(k) Number (if known): K092433
Device Name: DySIS Digital Colposcope
Indications for Use:
DySIS with Pseudo-Color Imaging (PCI) is a digital colposcope designed to image the cervix and lower genital tract under illumination and magnification. Colposcopy is indicated for women with an abnormal Pap smear in order to affirm normality or detect abnormal appearances consistent with neoplasia, often with directed biopsy.
The PCI feature is an adjunctive tool for displaying areas of acetowhitening. It is a tool that should NOT be used as a substitute for a thorough colposcopic evaluation.
Prescription Use _ X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Norma J. Perry